Fibrolamellar Hepatocellular Carcinoma: An Immunohistochemical Comparison With Conventional Hepatocellular Carcinoma

Abstract

The fibrolamellar variant of hepatocellular carcinoma (FLC) differs from conventional hepatocellular carcinoma (HCC) in some clinical and pathological features. The authors investigated possible differences in reactivity between FLCs and HCCs using glypican-3 (GPC3), an oncofetal protein, and survivin, an antiapoptotic protein. They also compared staining of FLC and HCC with antibodies to cytokeratins 7 (CK7) and 19 (CK19) and CD34. GPC3 was significantly more often and more strongly expressed in HCCs (72%) than in FLCs (17%). Survivin nuclear translocation in tumor cells did not differ between HCCs (10%) and FLCs (9%). There was more abundant expression of CK7 in FLCs (92%) than in HCCs (33%), whereas CK19 was more often found in HCCs (20%) than in FLCs (5%). All tumors had CD34-positive sinusoids. This study shows that FLCs and HCCs differ in the expression of GPC3, CK7, and CK19 and that there is a lack of difference as regards survivin and CD34.

Keywords

glypican-3 survivin CK7 hepatocellular carcinoma fibrolamellar carcinoma immunohistochemistry

Get full access to this article

View all access options for this article.

References

Ishak KG , Goodman ZD , Stocker JT , eds. Tumors of the Liver and Intrahepatic Bile Ducts. Washington, DC: Armed Forces Institute of Pathology ; 2001. Atlas of Tumor Pathology, Third Series, Fascicle 31.

Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007;14: 217-223.

Bosch FX , Ribes J. , Diaz M. , Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology . 2004;127:S5-S16.

El-Sarag HB Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34.

Berman MA , Burnham JA , Sheahan DG Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Human Pathol . 1988;19:784-794.

Scoazec JY , Flejou JF , D’Errico A. , et al. Fibrolamellar carcinoma of the liver: composition of the extracellular matrix and expression of cell-matrix and cell-cell adhesion molecules. Hepatology. 1996;24:1128-1136.

Schoedel KE , Tyner VZ , Kim TH , Michalopoulos GK , Mars WM HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod Pathol . 2003;16:14-21.

Klein WM , Molmenti EP , Colombani PM , et al. Primary liver carcinoma arising in people younger than 30 years . Am J Clin Pathol. 2005;124:512-518.

Kakar S. , Burgart LJ , Batts KP , Garcia J. , Jain D. , Ferrell LD Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis . Mod Pathol. 2005; 8:1417-1423.

10.

Peters MG , Farias E. , Colombo L. , Filmus J. , Puricelli L. , Bal de Kier Joffe E. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat. 2003 ;80:221-232.

11.

Nakatsura T. , Kageshita T. , Ito S. , et al. Identification of glypican-3 as a novel tumor marker for melanoma . Clin Cancer Res. 2004;10:6612-6621.

12.

Zynger DL , Dimov ND , Luan C. , Teh BT , Yang XJ Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.

13.

Capurro M. , Wanless IR , Sherman M. , et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97.

14.

Yamauchi N. , Watanabe A. , Hishinuma M. , et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma . Mod Pathol. 2005;18:1591-1598.

15.

Libbrecht L. , Severi T. , Cassiman D. , et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006;30:1405-1411

16.

Wang XY , Degos F. , Dubois S. , et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-1441.

17.

Llovet JM , Chen Y. , Wurmbach E. , et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology . 2006;131:1758-1767.

18.

Di Tommaso L. , Franchi G. , Park YN , et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725-734.

19.

LaCasse EC , Baird S. , Korneluk RG , MacKenzie AE The inhibitors of apoptosis (IAPs) and their emerging role in cancer . Oncogene. 1998;17:3247-3259.

20.

Deveraux QL , Reed JC IAP family proteins-suppressors of apoptosis . Genes Dev. 1999;13:239-252.

21.

Ito T. , Shiraki K. , Sugimoto K. , et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000;31:1080-1085.

22.

Moon WS , Tarnawski AS Nuclear translocation of surviving in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol. 2003 ;34:1119-1126.

23.

Fields A. , Cotsonis G. , Sexton D. , Santoianni R. , Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol . 2004;17:1378-1385.

24.

Hsu SM , Raine L. , Fanger H. Use of avidin-biotin-perioxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody procedures. J Histochem Cytochem. 1981;29:577-580.

25.

Filmus J. , Selleck SB Glypicans: proteoglycans with a surprise. J Clin Invest . 2001;108:497-501.

26.

Grozdanov PN , Yovchev MI , Dabeva MD The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/ oval cells. Lab Invest. 2006;86:1272-1284.

27.

Moon WS , Tarnawski AS Nuclear translocation of surviving in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol. 2003 ;34:1119-1126.

28.

29.

Wu PC , Fang JW , Lau VK , Lai CL , Lo CK , Lau JY Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers: clinical and biological implications . Am J Pathol. 1996;149:1167-1175.

30.

Durnez A. , Verslype C. , Nevens F. , et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology. 2006;49:138-151.

31.

Van Eyken P. , Sciot R. , Brock P. , Casteels-Van Daele M. , Ramaekers FCS , Desmet VJ Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver . Histopathology. 1990;17:101-107.

32.

Van Eyken P. , Sciot R. , Desmet VJ A cytokeratin immunohistochemical study of cholestatic liver disease: evidence that hepatocytes can express "bile duct-type" cytokeratins. Histopathology. 1989;15:125-135.

33.

Dhillon AP , Colombari R. , Savage K. , Scheuer PJ An immunohistochemical study of the blood vessels within primary hepatocellular tumours. Liver. 1992;12:311-318.

34.

Ruck P. , Xiao JC , Kaiserling E. Immunoreactivity of sinusoids in hepatocellular carcinoma: an immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34. Arch Pathol Lab Med. 1995;119:173-178.

35.

Tanigawa N. , Lu C. , Mitsui T. , Miura S. Quantification of sinusoidal-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology. 1997;26:1216-1223.

36.

Kimura H. , Nakajima T. , Kagawa K. , et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver. 1998;18:14-19.